Fortress Biotech

Fortress Biotech is a biopharmaceutical company with a diversified pipeline of over 20 candidates in various phases of development and markets dermatology products through Journey Medical Corporation.

Pipeline and Development

Fortress Biotech maintains a diversified pipeline with over 20 candidates in various stages of pre-clinical and clinical development. This extensive pipeline demonstrates the company's commitment to advancing medical science and developing innovative treatments across multiple domains. The diverse range of candidates ensures a robust approach to addressing various unmet medical needs.

Dermatology Products

Fortress Biotech markets several dermatology products through its partner company, Journey Medical Corporation. This partnership enables the distribution and commercialization of dermatological treatments, expanding the company's footprint within the dermatology sector. The collaboration leverages the expertise of Journey Medical Corporation to bring effective dermatological solutions to market.

Strategic Partnerships

Fortress Biotech has established strategic partnerships with leading academic research institutions and biopharmaceutical companies. These partnerships foster a collaborative environment for the development of novel therapies and the advancement of biotechnological research. Collaborating with renowned institutions enhances the company's capabilities in innovating and bringing new treatments to the public.

Licensing Agreements

Fortress Biotech has entered into multiple exclusive worldwide licensing agreements to expand its therapeutic offerings. Notably, they have an agreement with AstraZeneca for BAER-101, a novel GABA A positive allosteric modulator. Other agreements include partnerships with City of Hope for CAR T cell therapies, Fred Hutchinson Cancer Research Center for MB-106 CAR T therapy, Nationwide Children’s Hospital for MB-108, an oncolytic virus, and The University of Texas Health Science Center at Houston for three traumatic brain injury programs. These agreements enable Fortress Biotech to leverage external innovations and researchers to further their therapeutic pipeline.